Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
... (not including breast and prostate cancer) or multiple
For the primary endpoint, ... metastasized to the bone, and to patients with multiple
myeloma, both groups who routinely suffer SREs," ... cancer (excluding breast and prostate cancer) or multiple
myeloma. Patients enrolled in this event-driven ...
Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
... inhibitor of HCV.
PSI-7851 Phase 1 multiple
Ascending Dose Study Overview
In June 2009, Pharmasset initiated a phase 1 multiple
ascending dose study with PSI-7851. The trial was ... dose study and HCV infected patients in the multiple
ascending dose study. PSI-7851 was generally safe ...
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
... III trial in patients with secondary progressive multiple
sclerosis (SPMS). In addition, there were no ... genes. It is estimated that up to 70% of all multiple
sclerosis patients are HLA-DR2 and/or HLA-DR4 ... for measuring impairment in MS.
Clay Walker's Band Against MS Foundation Donates $150,000 To Support Multiple Sclerosis Research
... off big for researchers looking for a cure for multiple
sclerosis. The researchers took home the top ... Pebble Beach. Wolinsky serves as director of the multiple
Sclerosis Research Group and Magnetic Resonance ... who was diagnosed with relapsing-remitting multiple
sclerosis in 1996. "My hope is that our support ...
More Gene Mutations Linked to Autism Risk
... the healthy controls. The complex combination of multiple
genetic duplications and deletions is thought to ... of 3,832 individuals from 912 families with multiple
children with ASDs from the AGRE cohort against ... said the latest findings reinforce the view that multiple
gene variants, both common and rare, may be ...
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
... significant reduction in blood glucose levels in multiple
animal species. Isis and its collaborators also ... Drug, Causes Robust and Sustained Glucosuria in multiple
Species and is Safe and Well-Tolerated," Dr. ... in glucose excretion in the urine in multiple
species including monkeys
Single Port Surgeries Now Performed at University Medical Center at Princeton
... In traditional laparoscopic surgery, doctors make multiple
"keyhole" incisions -- usually three or four -- ... however, still had to recover from these multiple
small incisions, and deal with the cosmetic issue of multiple
In single port laparoscopic surgery, ...
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
... "We continue to see the potential of Afinitor in multiple
types of cancer," said Alessandro Riva, MD, ... everolimus showed anticancer activity across multiple
types of lymphoma, including T-cell non-Hodgkin's ... kidney cancer. Afinitor is being studied in multiple
cancer types, including NET, breast, gastric and ...
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
... improvements as compared to placebo in multiple
secondary endpoints associated with ... Research Center. "Lorcaserin's positive impact on multiple
secondary measures has important implications for ... significant improvements compared to placebo in multiple
secondary endpoints associated with ...
Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox
... Ethicon Endo-Surgery, Inc. today announced that multiple
studies presented at the 2009 Digestive Disease ... platform stability and adaptability to be used in multiple
interventions and procedures. The surgical ... transgastrically and transvaginally completing multiple
key surgical activities that included dissection, ...
Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
... of biomarkers in patients who received multiple
PROMETHEUS IBD Serology 7 tests within a two-year ... large patient cohort further confirmed that using multiple
markers combined with Prometheus' Smart ... markers alone. PROMETHEUS IBD Serology 7 combines multiple
serologic markers with a proprietary Smart ...
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
... was consistently superior to placebo across multiple
efficacy endpoints. At week 12, the CDAI greater ... platform, ChemoCentryx has internally generated multiple
clinical and preclinical-stage programs, each ... to treat diseases such as Type 2 diabetes, multiple
sclerosis and vascular restenosis, and CCX354, a ...
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
... Rate in Phase 2 Trial of Relapsed and Refractory multiple
Myeloma Patients - Proteolix Expands Trial
... survival in patients with relapsed and refractory multiple
myeloma. Carfilzomib is the first in a new class ... Phase 2 clinical trial of relapsed and refractory multiple
myeloma patients were presented today in an oral ...
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
... 2. The recent initiation of Phase 1 studies in multiple
myeloma and leukemia will allow us to extend the ... with a unique kinase selectivity profile and multiple
mechanisms of action. Preclinical studies with ... activity, including tumor regression, in multiple
solid and hematological malignancies. ENMD-2076 ...
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
... or metastatic solid tumors who have failed multiple
prior treatments are encouraging, with a number ... the treatment benefits of carfilzomib in multiple
treatment settings. We expect to complete the ... our late-stage clinical studies of carfilzomib in multiple
myeloma, and we are actively planning a Phase 3 ...
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
... meeting. These studies provide new research on multiple
tumor types and rare cancers.
To view the ... + lenalidomide and dexamethasone Phase I trial in multiple
In this first Phase I ... were safe when administered to patients with multiple
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
... support its broad worldwide market potential for multiple
indications beyond small cell lung cancer."
... variety of solid tumors. It is being studied in multiple
cancer indications, treatment combinations and by ... in solid tumors, and is being studied in multiple
cancer indications, combinations and ....
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
... to treat patients with relapsing-remitting multiple
sclerosis (MS). The results of the pivotal trial ... Tablets in this study was effective across multiple
important clinical and MRI efficacy measures," ... Merck Serono. "This is an exciting development in multiple
sclerosis clinical research, and represents an ...
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
... clinical trial to evaluate this molecule against multiple
types of solid tumors has been recently ... It is over-expressed in prostate hyperplasia and multiple
types of cancer including prostate cancer, breast ... that targets TRPM8 that could be applicable to multiple
types of cancer as well as BPH. The Company has ...
Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
... candidate that has potential applicability to multiple
types of cancer as well as to benign prostatic ... It is over-expressed in prostate hyperplasia and multiple
types of cancer including prostate cancer, breast ... that targets TRPM8 that could be applicable to multiple
types of cancer as well as BPH. The Company has ...
New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
... from patients with a type of blood cancer called multiple
myeloma, have shown that the antibody works with ... reduce the number of cancerous cells in multiple
myeloma patients and improve patient health and ... has commenced a Phase 1 trial in patients with multiple
myeloma and to date six patients have been ...
Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
... fingolimod (FTY-720) --- for the treatment of multiple
sclerosis will be in the first line. Surveyed ... The new report entitled Treatment Algorithms in multiple
Sclerosis also finds that only 38.8 percent of ... of relapsing-remitting patients (the dominant multiple
sclerosis subtype), they are less likely to ...
XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
... Erythropoietin ("rHuEPO") for the prolongation
myeloma ("MM") patients' survival and improvement ... disease and
Currently incurable, MM is a ... will be developing rHuEPO for the
treatment of multiple
myeloma. XTL is publicly traded on the NASDAQ ...
Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
... in its CRIMP (Control Resulting from Inhibiting multiple
Pathways) kinase platform by designing a small ... signaling pathway, a promising target pathway for multiple
disorders, including the company's focus - ... to identify and design inhibitors that block multiple
For more information see the ...
DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
... In addition, a non-clinical package comprising multiple
animal safety studies has been developed, ... carcinogenicity studies, long-term toxicology and multiple
Phase IIb Trial ... and other matters, patients were randomized into multiple
titration regimens. After achieving an endpoint ...
Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
... at the initiation of acne therapy to inhibit multiple
pathogenic factors. The new fixed combination, ... lives. The disorder is thought to be caused by multiple
factors. Overproduction of sebum, a normal oily ... As a result, combination therapy targeting the multiple
components of acne is now commonplace. In the ...
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
... in patients with relapsed/refractory multiple
myeloma. The data, which was presented earlier today in a poster featured at the 12th International multiple
Myeloma Workshop in Washington, DC, highlights a ... Patients with Relapsed or Relapsed / Refractory multiple
Myeloma Who Were Previously Treated with ...
Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
... product candidate for the treatment of multiple
sclerosis. ARX424 was created by Ambrx through ... harness the potential of our growth hormone and multiple
sclerosis product candidates given their ... patients with cancer (Erbitux(R), cetuximab), multiple
sclerosis (Rebif(R), interferon beta-1a), ...
Young Smokers Increase Risk for Multiple Sclerosis
... age 17 may increase their risk for developing multiple
sclerosis (MS), according to a study released ... environmental factors play a prominent role in multiple
sclerosis," said study author Joseph Finkelstein, ... disorders of the brain and nervous system such as multiple
sclerosis, restless legs syndrome, Alzheimer's ...
Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
Zometa is indicated for patients with multiple
myeloma and documented bone metastases from solid ... include impaired baseline renal function and multiple
cycles of bisphosphonate treatment.
Zometa ... ONJ based on tumor type (advanced breast cancer, multiple
myeloma) and dental status (dental extraction, ...
Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
... for the Treatment of Relapsed or Refractory multiple
LOS ANGELES, Feb. 11 /PRNewswire/ ... (bortezomib) is approved for the treatment of multiple
myeloma alone and in addition to chemotherapy. ... Research, this US-based Phase 1 study included 39 multiple
myeloma patients at three clinical oncology ....
EntreMed Presents Initial Clinical Results for ENMD-2076
... Designation from the FDA for the treatment of multiple
myeloma using ENMD-2076. To further enhance its ... designation for ENMD-2076 for the treatment of multiple
myeloma. The FDA accepted the Company's ... studies. A Phase 1 study with ENMD-2076 in multiple
myeloma is currently underway. Orphan drug is a ...
New Study Proves Multiple Births From IVF Can Be Avoided
... Single Embryo Transfer is Effective in Reducing multiple
ROCKVILLE, Md., Feb. 3 ... the nation bemoan the health risk and expense of multiple
births such as the octuplets born last Monday in ... when freed from financial pressures to transfer multiple
embryos, which can occur when patients have ...
Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment
... CPR analyzes each
investigator site for multiple
criteria to identify the optimal sites ...
In a three-year retrospective analysis of multiple
trials, Inclinix found
that investigators located ... Clients
benefit from ten years of experience in multiple
therapeutic areas, as well as
leading edge ...
Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
... Company Expects to Deliver multiple
Clinical Milestones throughout the Year; Amigal ... and presented a corporate outlook consisting of multiple
clinical milestones and financial guidance for ... evaluation of the safety and pharmacodynamics of multiple
doses and regimens of AT2220. The results of this ...
Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
... advanced solid tumors, Castleman's disease, or multiple
myeloma. The primary endpoints of the oral dose ... dose for Phase II trials. In addition, multiple
mechanism-related pharmacodynamic biomarkers that ... CK2 contributes to the cancer phenotype via multiple
cellular events, CX-4945 has been designed with ...
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
... is indicated for the treatment of
patients with multiple
myeloma who have not previously received VELCADE ... injury
- In the randomized multiple
myeloma study, 25 patients (8%) in the
... of DOXIL
- In patients with multiple
myeloma, hematologic toxicity (based on
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
... with bortezomib (+/- dexamethasone) in multiple
myeloma patients relapsed from or refractory to ... in patients with relapsed/refractory multiple
myeloma. The data was presented earlier today at ... Clinical Director of the Jerome Lipper multiple
Myeloma Center at the Dana-Farber Cancer ...
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
... for patients with previously untreated multiple
myeloma given VELCADE, melphalan and prednisone ... )
"The ultimate goal in treating multiple
myeloma is to prolong the patient's life," said ... advantage for patients with previously untreated multiple
The VISTA trial enrolled 682 ...
New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
... open label-trial of Bortezomib in patients with multiple
myeloma who have undergone high-dose melphalan ... Tumor Lysis Syndrome
Jeffrey Matous, M.D., ... in adult patients with advanced refractory multiple